Limits...
Selenium, selenoprotein genes and Crohn's disease in a case-control population from Auckland, New Zealand.

Gentschew L, Bishop KS, Han DY, Morgan AR, Fraser AG, Lam WJ, Karunasinghe N, Campbell B, Ferguson LR - Nutrients (2012)

Bottom Line: Serum selenium levels were significantly lower in CD patients compared to controls (101.8 ± 1.02 vs. 111.1 ± 1.01 ng/mL) (p = 5.91 × 10(-8)).These three SNPs have not been reported elsewhere as being significantly associated with selenium or CD.It is unclear as to whether lower selenium levels are a cause or an effect of the disease.

View Article: PubMed Central - PubMed

Affiliation: Discipline of Nutrition, FM&HS, University of Auckland, New Zealand. l.gentschew@ikmb.uni-kiel.de

ABSTRACT
New Zealand has one of the highest incidence rates of Crohn's Disease (CD), whilst the serum selenium status of New Zealanders is amongst the lowest in the world. A prospective case-control study in Auckland, New Zealand considered serum selenium as a potential CD risk factor. Serum selenium levels were significantly lower in CD patients compared to controls (101.8 ± 1.02 vs. 111.1 ± 1.01 ng/mL) (p = 5.91 × 10(-8)). Recent detailed studies in the United Kingdom have suggested an optimal serum level around 122 ng/mL, making the average CD patient in New Zealand selenium deficient. Of the 29 single nucleotide polymorphisms (SNPs) tested, 13 were found to significantly interact with serum selenium on CD. After adjustment for multiple testing, a significant interaction with serum selenium on CD was found for three SNPs, namely rs17529609 and rs7901303 in the gene SEPHS1, and rs1553153 in the gene SEPSECS. These three SNPs have not been reported elsewhere as being significantly associated with selenium or CD. It is unclear as to whether lower selenium levels are a cause or an effect of the disease.

Show MeSH

Related in: MedlinePlus

Distribution of serum selenium measures by CD and control group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3475235&req=5

nutrients-04-01247-f001: Distribution of serum selenium measures by CD and control group.

Mentions: Serum selenium levels were significantly lower in CD patients compared to controls (p = 5.91 × 10−8, Table 1). The mean serum selenium concentration for CD patients was 101.8 ng/mL and 111.1 ng/mL for the controls (Table 1 and Figure 1). Serum selenium was divided into tertiles representing low (<100.5 ng/mL), medium (100.5–118.5 ng/mL) and high levels (>118.5 ng/mL). Thereby, a significantly higher risk of having CD was observed in individuals in the lower selenium group as compared with those in the high selenium group and compared with those in the medium selenium group. No significant difference was found between medium and high selenium groups (Table 2), suggesting that there is a level of serum selenium that is adequate and higher levels may offer no benefit.


Selenium, selenoprotein genes and Crohn's disease in a case-control population from Auckland, New Zealand.

Gentschew L, Bishop KS, Han DY, Morgan AR, Fraser AG, Lam WJ, Karunasinghe N, Campbell B, Ferguson LR - Nutrients (2012)

Distribution of serum selenium measures by CD and control group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3475235&req=5

nutrients-04-01247-f001: Distribution of serum selenium measures by CD and control group.
Mentions: Serum selenium levels were significantly lower in CD patients compared to controls (p = 5.91 × 10−8, Table 1). The mean serum selenium concentration for CD patients was 101.8 ng/mL and 111.1 ng/mL for the controls (Table 1 and Figure 1). Serum selenium was divided into tertiles representing low (<100.5 ng/mL), medium (100.5–118.5 ng/mL) and high levels (>118.5 ng/mL). Thereby, a significantly higher risk of having CD was observed in individuals in the lower selenium group as compared with those in the high selenium group and compared with those in the medium selenium group. No significant difference was found between medium and high selenium groups (Table 2), suggesting that there is a level of serum selenium that is adequate and higher levels may offer no benefit.

Bottom Line: Serum selenium levels were significantly lower in CD patients compared to controls (101.8 ± 1.02 vs. 111.1 ± 1.01 ng/mL) (p = 5.91 × 10(-8)).These three SNPs have not been reported elsewhere as being significantly associated with selenium or CD.It is unclear as to whether lower selenium levels are a cause or an effect of the disease.

View Article: PubMed Central - PubMed

Affiliation: Discipline of Nutrition, FM&HS, University of Auckland, New Zealand. l.gentschew@ikmb.uni-kiel.de

ABSTRACT
New Zealand has one of the highest incidence rates of Crohn's Disease (CD), whilst the serum selenium status of New Zealanders is amongst the lowest in the world. A prospective case-control study in Auckland, New Zealand considered serum selenium as a potential CD risk factor. Serum selenium levels were significantly lower in CD patients compared to controls (101.8 ± 1.02 vs. 111.1 ± 1.01 ng/mL) (p = 5.91 × 10(-8)). Recent detailed studies in the United Kingdom have suggested an optimal serum level around 122 ng/mL, making the average CD patient in New Zealand selenium deficient. Of the 29 single nucleotide polymorphisms (SNPs) tested, 13 were found to significantly interact with serum selenium on CD. After adjustment for multiple testing, a significant interaction with serum selenium on CD was found for three SNPs, namely rs17529609 and rs7901303 in the gene SEPHS1, and rs1553153 in the gene SEPSECS. These three SNPs have not been reported elsewhere as being significantly associated with selenium or CD. It is unclear as to whether lower selenium levels are a cause or an effect of the disease.

Show MeSH
Related in: MedlinePlus